← Back to guidelines
Hematology34 papers

Myelodysplastic neoplasm

Last edited: 4/10/2026

Overview

Myelodysplastic neoplasms (MDS) are a heterogeneous group of distinct entities characterized by ineffective hematopoiesis 1. Recent classification systems further subcharacterize MDS into morphologically and genetically defined groups 1.

Diagnosis

  • Accurate diagnosis and subclassification require a multistep, systemic, and multimodal approach 1.
  • Key diagnostic and subclassification frameworks include the 5th edition of the World Health Organization Classification of Haematolymphoid Tumours and the International Consensus Classification 1.
  • Management

  • Management strategies are guided by the specific subtype of MDS 1.
  • Key Recommendations

  • Accurate diagnosis and subclassification of MDS require a multistep, systemic, and multimodal approach 1. (Evidence: Expert opinion)
  • Contemporary classification systems, such as the 5th edition of the WHO Classification of Haematolymphoid Tumours and the International Consensus Classification, further subcharacterize MDS into morphologically and genetically defined groups 1. (Evidence: Expert opinion)
  • References

    1 Aakash F, Gisriel SD, Zeidan AM, Bennett JM, Bejar R, Bewersdorf JP et al.. Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]). Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2024. link

    Original source

    1. [1]
      Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]).Aakash F, Gisriel SD, Zeidan AM, Bennett JM, Bejar R, Bewersdorf JP et al. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc (2024)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG